BI 1584862 + midazolam

BI 1584862 + midazolam is a drug combination primarily utilized in clinical pharmacology research to assess the drug-drug interaction (DDI) profile of BI 1584862. BI 1584862 is a small molecule agonist of the G-protein coupled receptor 119 (GPR119), a target found on pancreatic beta cells and intestinal L-cells that regulates insulin secretion and incretin release. Developed by Boehringer Ingelheim, BI 1584862 was investigated for the treatment of type 2 diabetes and obesity. Midazolam is a short-acting benzodiazepine that functions as a positive allosteric modulator of the GABA-A receptor and is widely used as a sensitive probe substrate for the cytochrome P450 3A4 (CYP3A4) enzyme. In clinical trials, such as NCT04114019, the co-administration of these two agents allows for the evaluation of whether BI 1584862 alters the metabolism of CYP3A4 substrates, which is critical for determining its safety and potential for interactions with other medications.